O’Farrell, Libbey S.
Eli Lilly (United States)
6 papers on CoChatORCID 0000-0002-2825-5270
Most cited papers
- Verified
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 316
- Verified
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation
Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases
Cited by 256
- Verified
Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation
Li, Y., Schnabl, K., Gabler, S.-M., Willershäuser, M., Reber, J., Karlas, A., Laurila, S., Lahesmaa, M., u Din, M., Bast-Habersbrunner, A., et al. (2018) · Cell
Adipose Tissue and MetabolismRegulation of Appetite and Obesity
Cited by 228
- Verified
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
Ravussin, E., Sanchez-Delgado, G., Martin, C. K., Beyl, R. A., Greenway, F. L., O’Farrell, L. S., Roell, W. C., Qian, H.-R., Li, J., Nishiyama, H., et al. (2025) · Cell Metabolism
Regulation of Appetite and ObesityPharmacology and Obesity Treatment
Cited by 72
- Verified
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., et al. (2024) · Science Translational Medicine
Diabetes Treatment and ManagementReceptor Mechanisms and Signaling
Cited by 52
- Verified
679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes
COSKUN, T., MOYERS, J. S., ROELL, W. C., O’FARRELL, L., REGMI, A., RUAN, X., SHOWALTER, A. D., SLOOP, K., WAINSCOTT, D. B., WILLARD, F. S., et al. (2021) · Diabetes
Diabetes Treatment and ManagementRegulation of Appetite and Obesity
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free